IHS Chemical Week

Regions :: India/Pakistan

Sun Pharma to acquire Ranbaxy for $3.2 billion

11:45 AM MDT | April 7, 2014 | Deepti Ramesh

Sun Pharmaceutical Industries (Mumbai) says it has agreed to acquire 100% of Ranbaxy Laboratories (Gurgaon, India) in an all-stock transaction, which has a total equity value of about $3.2 billion. The combination of Sun Pharma and Ranbaxy will create the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India. Ranbaxy shareholders, under the agreement, will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The proposed acquisition has been approved by the boards of directors of Sun Pharma and Ranbaxy as well...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa